Roger1, on the AV side, over the years Dr. Thorpe has used some of his strongest language in describing Bavi’s ability to thwart LASSA FEVER, including its ability to confur immunity to further infection. Of course, LASSA is one of the 3 main VIRAL HEMORRHAGIC FEVERS, along with EBOLA & MARBURG, which are the very target of PPHM’s 5-yr $44mm DTRA Contract ( http://tinyurl.com/5dxpup ).
4-4-05: Dr. Thorpe tells AAI Conference: “Surviving animals (50%) showed no signs of viral infection several mos. after treatment with Bavituximab and were considered disease free; they developed long-term immunity to further infection with the Pichinde virus [Lassa Fever Model]. Since Bavituximab targets a basic, universal property of enveloped viruses that is host-derived & indep. of the viral genome, it may be effective against a broad spectrum of enveloped viruses. This target may also be difficult for viruses to overcome via resistance mechanisms." http://tinyurl.com/9ktvsb
10-24-06 Annual SHM… Dr. Thorpe: And when we treated guinea pigs who had advanced Lassa Fever-related viral infection, 50% of the guinea pigs went on to be permanently disease-free responders, and were actually resistant to re-infection with the same virus – a remarkable result given the severity of the disease.” http://tinyurl.com/vmasl
5-2007: Thorpe/Soares AAI IMMUNOLOGY’07/ Bavi/AV Poster: “Direct clearance of free virus and antibody-dependent cellular cytotoxicity of virus-infected cells appear to be the major mechanisms that contribute to the anti-viral effect of bavituximab. Bavituximab-treated survivors were immune to reinfection.” http://tinyurl.com/2tf8df & http://tinyurl.com/3cxk2d
8-5-09: ‘New Scientist’ Article Highlights BaviAV… Dr. Thorpe: "We were doing something that was quite extraordinary. We had let the animals progress in their disease [Lassa Fever] until they were heavily symptomatic, and then started treatment. It was a major accomplishment to knock that disease back." http://tinyurl.com/mp2aku
Market Data 
Markets 
AI
